2023 World Conference on Lung Cancer (Posters)-EP14.01. Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients treated with Intracavitary Cisplatin-Fibrin

EP14.01. Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients treated with Intracavitary Cisplatin-Fibrin - PDF(Abstract)

Back to course

Pdf Summary

Researchers from the University Hospital Zurich presented their findings on the prognostic value of Ki-67 expression in patients with pleural mesothelioma (PM) who were treated with intracavitary cisplatin-fibrin. The study explored novel therapeutic approaches for patients with PM, a cancer caused by asbestos exposure.<br /><br />The researchers conducted phase I and II clinical trials for localized chemotherapy with cisplatin-fibrin after surgery (INFLuenCe-Meso) and aimed to identify biomarkers associated with outcomes for future patient selection.<br /><br />Tissues collected at diagnosis (pre-CTX) were available from 5 patients, and tumor tissues at surgery (post-CTX) were collected from all enrolled patients (n=25). The tissues were stained via immunohistochemistry for potential markers, including p21 (cisplatin resistance) and Ki-67 (proliferation).<br /><br />The results showed that a low Ki-67 staining index was significantly associated with better progression-free survival (PFS) and overall survival (OS) outcomes. High Ki-67 labeling index was associated with shorter PFS and OS. There was no association between clinical parameters and Ki-67 or p21 staining.<br /><br />In a subset of patients with available pre- and post-CTX tissue, a reduction in Ki-67 index was observed after chemotherapy in 3 cases. However, the relationship between this change and the response to chemotherapy and intracavitary treatment is still under investigation.<br /><br />The researchers concluded that although the patient cohort was small, Ki-67 showed a significant association with disease outcomes in patients receiving localized cisplatin-fibrin treatment. They are currently assessing Ki-67 in more tissues collected at diagnosis to confirm the association with survival before therapy. Ki-67 may prove useful as a biomarker for patient selection for this treatment regimen.

Asset Subtitle

Michaela Kirschner

Meta Tag

Speaker Michaela Kirschner

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

University Hospital Zurich

prognostic value

Ki-67 expression

pleural mesothelioma

intracavitary cisplatin-fibrin

biomarkers

patient selection

immunohistochemistry

progression-free survival

overall survival